<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?properties manuscript?><front><journal-meta><journal-id journal-id-type="nlm-journal-id">101740247</journal-id><journal-id journal-id-type="nlm-ta">AAS Open Res</journal-id><journal-id journal-id-type="iso-abbrev">AAS Open Res</journal-id><journal-title-group><journal-title>AAS open research</journal-title></journal-title-group><issn pub-type="epub">2515-9321</issn></journal-meta><article-meta><article-id pub-id-type="pmid">31517248</article-id><article-id pub-id-type="pmc">6742509</article-id><article-id pub-id-type="manuscript">EMS84056</article-id><article-id pub-id-type="doi">10.12688/aasopenres.12925.1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Association between CD4 T cell counts and the immune status among
adult critically ill HIV-negative patients in intensive care units in
Uganda</article-title><fn-group content-type="pub-status"><fn id="FN1"><p id="P1">[version 1; peer review: 1 approved, 2 approved with
reservations]</p></fn></fn-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Kavuma Mwanje</surname><given-names>Arthur</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data Curation</role><role content-type="http://credit.casrai.org/">Formal Analysis</role><role content-type="http://credit.casrai.org/">Funding Acquisition</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project Administration</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; Original Draft
Preparation</role><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1249-3258</contrib-id><xref rid="C1" ref-type="corresp">a</xref><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author" corresp="no"><name><surname>Ejoku</surname><given-names>Joseph</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project Administration</role><role content-type="http://credit.casrai.org/">Supervision</role><xref ref-type="aff" rid="A3">3</xref><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author" corresp="no"><name><surname>Ssemogerere</surname><given-names>Lameck</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data Curation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; Original Draft
Preparation</role><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3117-1350</contrib-id><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author" corresp="no"><name><surname>Lubulwa</surname><given-names>Clare</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data Curation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Supervision</role><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author" corresp="no"><name><surname>Namata</surname><given-names>Christine</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data Curation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; Original Draft
Preparation</role><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" corresp="no"><name><surname>Kwizera</surname><given-names>Arthur</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data Curation</role><role content-type="http://credit.casrai.org/">Formal Analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; Original Draft
Preparation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; Review &#x00026;
Editing</role><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" corresp="no"><name><surname>Wabule</surname><given-names>Agnes</given-names></name><role content-type="http://credit.casrai.org/">Data Curation</role><role content-type="http://credit.casrai.org/">Formal Analysis</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project Administration</role><role content-type="http://credit.casrai.org/">Writing &#x02013; Original Draft
Preparation</role><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" corresp="no"><name><surname>Okello</surname><given-names>Erasmus</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data Curation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; Original Draft
Preparation</role><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" corresp="no"><name><surname>Kizito</surname><given-names>Samuel</given-names></name><role content-type="http://credit.casrai.org/">Data Curation</role><role content-type="http://credit.casrai.org/">Formal Analysis</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Software</role><role content-type="http://credit.casrai.org/">Writing &#x02013; Original Draft
Preparation</role><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author" corresp="no"><name><surname>Lubikire</surname><given-names>Aggrey</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data Curation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; Original Draft
Preparation</role><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" corresp="no"><name><surname>Sendagire</surname><given-names>Cornelius</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data Curation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; Original Draft
Preparation</role><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author" corresp="no"><name><surname>Andia Biraro</surname><given-names>Irene</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; Original Draft
Preparation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; Review &#x00026;
Editing</role><xref ref-type="aff" rid="A6">6</xref><xref ref-type="aff" rid="A7">7</xref></contrib><aff id="A1">
<label>1</label>Department of Anaesthesia, Makerere University, Kampala, 256,
Uganda</aff><aff id="A2">
<label>2</label>Department of Anaesthesia, Holy Cross Orthodox Hospital,
Kampala, 256, Uganda</aff><aff id="A3">
<label>3</label>Department of Anaesthesia, Uganda Heart Institute, Kampala, 256,
Uganda</aff><aff id="A4">
<label>4</label>Department of Anaesthesia, Mulago National Referral Hospital,
Kampala, 256, Uganda</aff><aff id="A5">
<label>5</label>Department of Clinical Epidemiology and Biostatistics, Makerere
University, Kampala, 256, Uganda</aff><aff id="A6">
<label>6</label>Medical Research Council, Uganda Virus Research-Institute Uganda
Research Unit on AIDS, Kampala, 256, Uganda</aff><aff id="A7">
<label>7</label>Department of Internal Medicine, Makerere University, Kampala,
256, Uganda</aff></contrib-group><author-notes><corresp id="C1"><label>a</label><email xlink:href="mailto:kart227@yahoo.com">kart227@yahoo.com</email></corresp><fn fn-type="COI-statement" id="FN2"><p id="P2">No competing interests were disclosed.</p></fn></author-notes><pub-date pub-type="epub"><day>8</day><month>1</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>12</day><month>9</month><year>2019</year></pub-date><volume>2</volume><elocation-id>2</elocation-id><permissions><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the
Creative Commons Attribution Licence, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><self-uri xlink:href="https://aasopenresearch.org/articles/2-2"/><abstract><p id="P3">
<bold>Background</bold>: Cluster of differentiation 4 (CD4) T cells play a
central role in regulation of adaptive T cell-mediated immune responses. Low CD4
T cell counts are not routinely reported as a marker of immune deficiency among
HIV-negative individuals, as is the norm among their HIV positive counterparts.
Despite evidence of mortality rates as high as 40% among Ugandan critically ill
HIV-negative patients, the use of CD4 T cell counts as a measure of the immune
status has never been explored among this population. This study assessed the
immune status of adult critically ill HIV-negative patients admitted to Ugandan
intensive care units (ICUs) using CD4 T cell count as a surrogate marker.</p><p id="P4">
<bold>Methods:</bold> A multicentre prospective cohort was conducted between
1<sup>st</sup> August 2017 and 1<sup>st</sup> March 2018 at four Ugandan
ICUs. A total of 130 critically ill HIV negative patients were consecutively
enrolled into the study. Data on sociodemographics, clinical characteristics,
critical illness scores, CD4 T cell counts were obtained at baseline and
mortality at day 28.</p><p id="P5">
<bold>Results:</bold> The mean age of patients was 45&#x000b1; 18 years
(mean&#x000b1;SD) and majority (60.8%) were male. After a 28-day follow up, 71
[54.6%, 95% CI (45.9-63.3)] were found to have CD4 counts less than 500
cells/mm&#x000b3;, which were not found to be significantly associated with
mortality at day 28, OR (95%) 1 (0.4&#x02013;2.4), p = 0.093. CD4 cell count
receiver operator characteristic curve (ROC) area was 0.5195, comparable to
APACHE II ROC area 0.5426 for predicting 24-hour mortality.</p><p id="P6">
<bold>Conclusions:</bold> CD4 T cell counts were generally low among
HIV-negative critically ill patients. Low CD4 T cells did not predict ICU
mortality at day 28. CD4 T cell counts were not found to be inferior to APACHE
II score in predicting 24 hour ICU mortality.</p></abstract><kwd-group kwd-group-type="author"><kwd>CD4 T cells</kwd><kwd>HIV negative</kwd><kwd>critically ill</kwd><kwd>immune status</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="S1"><title>Introduction</title><p id="P7">Cluster of differentiation 4 (CD4) is a glycoprotein found on the surface of
immune cells such as T helper cells and macrophages<xref rid="R1" ref-type="bibr">1</xref>. If CD4 T cells become depleted, the body is left susceptible to a
wide spectrum of viral and bacterial infections that it would otherwise have been
able to fight<xref rid="R2" ref-type="bibr">2</xref>. CD4 T cells play a central
role in the cascade of events forming immune response to foreign antigen, hence
monitoring their levels is necessary to understand the extent of immune
deficiency<xref rid="R3" ref-type="bibr">3</xref>. A normal CD4 T cell count in
an adult is usually between 500 and 1500 cells/mm&#x000b3;<xref rid="R4" ref-type="bibr">4</xref>. Low CD4 T cell levels are reported in HIV-positive
patients as a marker of poor immune status and may fall to as low as zero cells in
peripheral blood. Similarly, CD4 T cells may be suppressed among HIV negative
patients that suffer from critical illnesses<xref rid="R5" ref-type="bibr">5</xref>.
CD4 T cell counts differ across different HIV-negative populations, due to a variety
of factors that include environmental, immunological and genetic factors<xref rid="R6" ref-type="bibr">6</xref>.</p><p id="P8">Critical care has become an important area of the health sciences, leading to
development of scoring systems to guide clinicians in estimating patients&#x02019;
prognoses, and in particular the risk of mortality. The most frequently used scoring
system is the Acute Physiology Age and Chronic Health Evaluation II (APACHE II)<xref rid="R7" ref-type="bibr">7</xref> which predicts mortality in the first 24 hours
of admission to ICU.</p><p id="P9">Low CD4 T cell counts were associated with mortality among HIV patients
admitted to African ICU<xref rid="R8" ref-type="bibr">8</xref>. Surprisingly, very
low CD4 T cell counts are fairly common among people without HIV, and are likely to
be present among 40 and 70% of people admitted to ICUs<xref rid="R9" ref-type="bibr">9</xref>.</p><p id="P10">No such study had been conducted in Uganda before; hence, no available
policies regarding use of CD4 T cell counts among critically ill HIV-negative
patients from the Ugandan Ministry of Health.</p></sec><sec sec-type="methods" id="S2"><title>Methods</title><sec id="S3"><title>Study background</title><p id="P11">We conducted a prospective cohort study between 1<sup>st</sup> August
2017 and 1<sup>st</sup> March 2018 at Mulago National Referral ICU, Uganda Heart
Institute ICU, International Hospital Kampala ICU and Nakasero Hospital Limited
ICU in Kampala city, Uganda. Baseline data on patients&#x02019; demographic
variables (employment status, education level, family income, smoking, age, sex
and ethnicity), admission diagnosis, CD4 T Cell counts and APACHE II scores were
collected. We included adult HIV negative critically ill, APACHE II scored,
medical/surgical ICU patients and excluded patients found admitted to ICU beyond
24 hours and those on immunosuppressant drugs such as steroids prior to
admission. A total of 130 critically ill HIV-negative adults were enrolled into
the study of which 127 participants gave written informed assent on behalf of
their critically ill patients while 3 were waived of consent by the ethics
committee because they had no proxies. The sample size was calculated using the
formula for sample size calculation for two groups with a continuous outcome as
outlined in Designing Clinical Research by Hulley <italic>et al.</italic><xref rid="R10" ref-type="bibr">10</xref>. <italic/> We aimed for power of 80%,
level of significance of 95% and using mean estimates of CD4 from a study<xref rid="R6" ref-type="bibr">6</xref>. All study participants were followed for
28 days and end of follow up survival and mortality data was collected.</p></sec><sec id="S4"><title>Patient assessment</title><p id="P12">Referring to World Health Organization, we grouped CD4 levels into two;
where CD4 above 500 cells/mm&#x000b3; signified immune competent or normal CD4
count and those with CD4 less than 500 cells/mm&#x000b3; reflecting low
immunity.</p><p id="P13">The APACHE II scores and blood draws for CD4 T cell counts were
performed upon admission between 8 am and 10 am. Blood sampling followed a
standard laboratory practice. Approximately 3 to 5 ml of blood were collected in
K3/K2 EDTA vacutainers, labeled with the patient&#x02019;s identification, date
and time of collection, and the name of the collecting personnel. To assess
patients&#x02019; CD4 levels, BD FACSCalibur anticoagulated blood samples
transported at ambient temperature (20&#x02013;25&#x000b0;C) was stained within 48
hours of draw and then analyzed within 6 hours of staining<xref rid="R11" ref-type="bibr">11</xref>. Samples were analysed from a 4-star laboratory of
Makerere-Mbarara University Joint AIDS Program. Sample transport was by hand
delivery and no transport was done on non-testing days. A coding manual for
laboratory results was developed for broken samples, insufficient, clotted,
frozen, haemolysed blood, samples not been drawn in K3/K2 EDTA vacutainers and
errors in laboratory procedures. </p><p id="P14">Strict procedures for data management during the pre-analytical,
analytical and post analytical phase of testing were conducted to ensure the
reliable production and delivery of accurate test results. Laboratory equipment
was calibrated daily and sample laboratory registers were used to record receipt
of samples and the production and release of results on entry of test result
form.</p><p id="P15">The collection sites maintained the test request form. Testing
laboratory had reliable systems for receiving and processing result data with
uniform basic data handling, storage and reporting standards. The testing
laboratory maintained records of result data for defined periods, to allow
repeat reporting of lost test results, as well as aggregation for monitoring and
evaluation or other research purposes. The testing laboratory also ensured
reliable and rapid delivery of results.</p></sec><sec id="S5"><title>APACHE II questionnaire</title><p id="P16">The questionnaires were cross-checked by the principal investigator (PI)
to ensure completeness before leaving the study site and periodically, the PI
arranged a meeting with the assistants to validate data. Computer in-built
checks reinforced data completeness. Quantitative data was double-entered to
ensure correctness of data entered. According to WHO guidelines, the
questionnaire was translated into Luganda a local dialect and back-translated
into English by K.A.M.</p><p id="P17">To address potential sources of bias, the PI and critical care nurses
(research assistants) sampled the participants by drawing blood and filling the
questionnaires that were retained at the study sites. The laboratory technician
(research assistant) transported all samples with only a laboratory request form
and did not participate in drawing blood from the patients, only K.A.M. accessed
the study results and strictly 130 participants were recruited and all completed
a 28-day follow-up.</p></sec><sec id="S6"><title>Ethical approval</title><p id="P18">This study was approved by Research and Ethics Committee of Makerere
University. A waiver of requirement for consent for unconscious patients without
proxies was obtained with a reference number 2017-095. Final approval was
granted by Uganda National Council for Science and Technology with a reference
number HS104ES.</p></sec><sec id="S7"><title>Data management and statistical analysis</title><p id="P19">An electronic database was created using <ext-link ext-link-type="uri" xlink:href="https://www.epidata.dk/">EpiData</ext-link>
version 3.1 to enter the raw data from the questionnaires. The data was then
transferred to STATA version 14.1 for analysis. In determining the CD4 T cell
counts among the study participants, we presented the mean CD4 count with its
corresponding standard deviation since it was normally distributed. In addition,
we presented the CD4 as a categorized variable with frequencies (and
percentages) for the various cutoffs with the corresponding 95% confidence
intervals of the proportions.</p><p id="P20">In order to determine the relationship between CD4 T cell counts and
28-day ICU mortality, we performed multivariate logistic regression with CD4
count as the main predictor and 28-day mortality as the outcome. Prior to
performing the multivariate logistic regression models, we performed bivariate
analysis and all the variables with a p-value of 0.2 or less were included in
the multivariate model.</p><p id="P21">Multivariate logistic regression was performed to determine how the CD4
jointly with other variables was associated with 28-day mortality. The variables
were entered into a stepwise logistic model. Significance was set at p-value of
0.05 or less. The goodness of fit of the final model was tested using the Hosmer
&#x00026; Lemeshow goodness of fit, testing the null hypothesis that the final model
adequately fits the data.</p><p id="P22">To assess the feasibility of using CD4 T cell counts to predict 24-hour
mortality, as compared to APACHE II score, we compared the area under the
Receiver Operator Characteristic Curves (ROC) between CD4 and APACHE II in
predicting mortality. Prior to generating the ROC, we generated the
sensitivities and specificities for the different cutoffs for both CD4 count and
APACHE II. The ROC was then generated with y-axis being sensitivity and the
x-axis being 1-specificity.</p></sec></sec><sec sec-type="results" id="S8"><title>Results</title><sec id="S9"><title>Patient characteristics</title><p id="P23">More than half (53.9%) of the participants were recruited from MNRH
followed by IHK (24.6%), NHL (19.2%) and lastly UHI (2.3%). Non-smoking
self-employed black males dominated the study population at a mean age of
45.2&#x000b1;18.3 (mean&#x000b1;SD) and a family income above $1 as shown in <xref rid="T1" ref-type="table">Table 1</xref>. The major indication for admitting
to ICU was postoperative high critical care requirements (46.2%), whilst the
least common was urinary tract infection (UTI) (0.8%). Details are shown in
<xref rid="T2" ref-type="table">Table 2</xref>. All raw data are available
on <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.17605/OSF.IO/JBMKP">OSF</ext-link><xref rid="R12" ref-type="bibr">12</xref>.</p></sec><sec id="S10"><title>CD4 T cell counts among critically ill HIV-negative patients</title><p id="P26">Overall 130 CD4 tests were carried out, of which 71 [54.6%, 95% CI
(45.9-63.3)] were low (less than 500 cells/mm&#x000b3;). The mean CD4 count was
494.4&#x000b1;282 cells/mm&#x000b3; (mean&#x000b1;SD), and the lowest count was 50
cells/mm&#x000b3;. Other details are shown in <xref rid="T3" ref-type="table">Table
3</xref>. There was no significant association in mortality outcome between
those who had normal (CD4 &#x02265;500 cells/mm&#x000b3;) and low (CD4 &#x0003c;500
cells/mm&#x000b3;) CD4 counts (p = 0.64). Other details are shown in <xref rid="T4" ref-type="table">Table 4</xref>.</p></sec><sec id="S11"><title>Relationship between CD4 T cell counts and 28-day mortality</title><p id="P28">At bivariate analysis, smoking, admitting a patient from another
hospital, ICUs for hospitals MNRH, NHL and UHI had a strong statistically
significant association with mortality at day 28. At multivariate analysis,
abnormal CD4 count was not found to be significantly associated with mortality
at day 28 in our population OR (95%) 1 (0.4&#x02013;2.4) p = 0.093. Other details
are shown in <xref rid="T5" ref-type="table">Table 5</xref>.</p></sec><sec id="S12"><title>Feasibility of using CD4 T cell counts to predict 24-hour mortality as
compared to APACHE II score</title><p id="P30">From the receiver operator characteristic curves for comparing CD4 cell
count and APACHE II score in predicting mortality, the area under the curve for
the two graphs was comparable (this signified that CD4 count could be as good as
APACHE II score). However, both graphs demonstrated very low area under the
curve (the closer to 1 the area is, the more diagnostically accurate the curve).
Therefore, the data signified that both APACHE II and CD4 were not good
predictors of the outcome, despite being comparable (<xref rid="F1" ref-type="fig">Figure 1</xref>).</p></sec></sec><sec sec-type="discussion" id="S13"><title>Discussion</title><sec id="S14"><title>Demographics and clinical characteristics</title><p id="P31">To our knowledge, this multicenter cohort study is the first report to
discuss the immune status of critically ill HIV-negative patients admitted to
Ugandan ICUs using CD4 T cell count as a surrogate marker. Almost all
participants were black, of African descent and non-smokers, because black
Africans, who rarely smoke, dominated the study population.</p><p id="P32">Most admissions from all the four ICUs were surgical cases and those
requiring high postoperative care contributed the highest number of participants
while the least was due to UTI. This is because MNRH is the referral center for
most critical patients and strictly to mention the trauma patients. The same
happened to UHI ICU that admitted mostly surgical cases.</p><p id="P33">In our study, we found that more than half of the participants had low
CD4 T cell counts This may have been caused by critical illness that led to
production of cortisol. This in turn may have suppressed the production of CD4 T
cells. Our findings agree with a study conducted in nine consecutive patients
admitted to the ICU with sepsis in Japan, whose CD4 cells were clearly reduced
below 500 cells/mm&#x000b3; and remained at that level for entire 4 weeks<xref rid="R13" ref-type="bibr">13</xref>. These findings are also in agreement
with a study conducted in HIV-negative Senegalese individuals, which found that
CD4 cell counts varied in HIV-negative individuals<xref rid="R6" ref-type="bibr">6</xref>. Though our study population was purely HIV negative, we found
that more than 50% of the participants had low CD4 cell counts, with four
participants having their CD4 cell counts as low as less than 50 cells/mm&#x000b3;
and six participants having counts less than 200 cells/mm&#x000b3;, values
considered to indicate AIDS in patients living with HIV. Hence critical illness
alone, without HIV infection, can present a picture that resembles that of AIDS
in HIV-negative critically ill patients.</p><p id="P34">We did not find a statistically significant association between CD4 T
cell counts and ICU mortality at day 28 among critically ill HIV-negative
patients in our population. This is consistent with a study conducted by Feeney
<italic>et al</italic>., which did not find whether low CD4 T cell counts
were associated with a poor prognosis<xref rid="R9" ref-type="bibr">9</xref>.
The reason why this American study agrees with our findings could be entirely
attributable to the sample size that is almost similar in both studies. However,
our results contradict with other studies that have shown that septic patients
with loss of CD4 T cells have a higher mortality<xref rid="R14" ref-type="bibr">14</xref>. It is also in contrast with a study conducted in 2007, which
showed that low CD4 T cell counts were associated with death<xref rid="R14" ref-type="bibr">14</xref>. Our findings could be ascribed to the fact that
CD4 T cells are a surrogate marker of the many immune cells. Hence, measuring
CD4 alone could not yield reliable information to predict mortality. Another
reason for the lack of statistical significance observed would be due to the
sample size and short-term follow-up that may be were not adequate to give
dependable results. It is also prudent to note that CD4 T cells were only
sampled once, hence making it hard to track the exact CD4 cells at the time of
the patient&#x02019;s demise.</p><p id="P35">Both high APACHE II and low CD4 count could predict a 24-hour mortality
in our population; however, despite being comparable, both were not good
predictors of mortality. This is in line with a study conducted in 2000, where
elevated APACHE II score remained a significantly negative predictor of survival
at 28-day mortality<xref rid="R15" ref-type="bibr">15</xref>. It also concurs
with a study conducted in 2015 that reported that the median APACHE II of 25
predicted greater than 50% mortality<xref rid="R8" ref-type="bibr">8</xref>. The
latter leaves a benefit of doubt, as the study did not report that mortality
would be 100%. However it is in contrast with a study done in 1995 that did not
find any relationship between CD4 counts and APACHE II score, predicted
mortality rate, or survival rate<xref rid="R9" ref-type="bibr">9</xref>.</p></sec></sec><sec sec-type="conclusions" id="S15"><title>Conclusion</title><p id="P36">From our study, we conclude that CD4 T cell counts were generally low among
HIV-negative critically ill patients and recommend that this indicator should be
incorporated onto the panel of baseline investigations in this group of patients. We
also established that low CD4 cells did not predict mortality at day 28 in our study
population, although it would predict 24-hour mortality and was not inferior to
prediction using APACHE II score. Hence, we suggest the use of CD4 T Cell counts in
resource constrained setup to help in directing proper use of resources. Critically
ill patients with low CD4 T cell counts should be supplemented with immunoadjuvant
therapy to restore their immune system and also prevent loss of functional T helper
cells as these play a major role in defending the body against pathogens. Further
multinational studies on serial CD4 sampling until patients&#x02019; demise and a
longer follow-up period are required.</p></sec><sec sec-type="data-availability" id="S16"><title>Data availability</title><p id="P37">Raw data associated with this study are available on OSF in csv and dta
formats. DOI: <ext-link ext-link-type="uri" xlink:href="https://dx.doi.org/10.17605/OSF.IO/JBMKP">https://doi.org/10.17605/OSF.IO/JBMKP</ext-link><xref rid="R12" ref-type="bibr">12</xref>.</p><p id="P38">Data are available under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">Creative Commons Zero "No rights reserved" data
waiver</ext-link> (CC0 1.0 Public domain dedication).</p></sec></body><back><ack id="SA1"><sec id="SA2"><title>Grant Information</title><p id="PF1">KAM, NC and AK are supported through the DELTAS Africa Initiative grant
#DEL-15-011 to THRiVE-2. The DELTAS Africa Initiative is an independent funding
scheme of the African Academy of Sciences (AAS)&#x02019;s Alliance for Accelerating
Excellence in Science in Africa (AESA) and supported by the New Partnership for
Africa&#x02019;s Development Planning and Coordinating Agency (NEPAD Agency),
with funding from the Wellcome Trust grant 107742 and the UK
government. The views expressed in this publication are those of the authors and
not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK
government.</p><p id="PF2">
<italic>The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.</italic>
</p></sec></ack><ref-list><ref id="R1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bernard</surname><given-names>A</given-names></name><name><surname>Boumsell</surname><given-names>L</given-names></name><name><surname>Hill</surname><given-names>C</given-names></name></person-group>: <article-title>Joint report of the first international workshop
on human leucocyte differentiation antigens by the investigators of the
participating laboratories</article-title>. In <italic>Leucocyte
typing</italic>
Springer.<year>1984</year>;<fpage>9</fpage>&#x02013;<lpage>142</lpage>.
<pub-id pub-id-type="doi">10.1007/978-3-642-68857-7_3</pub-id>
</mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Asadi</surname><given-names>S</given-names></name><name><surname>Heydari</surname><given-names>E</given-names></name></person-group>: <article-title>Effectiveness Mir-93, Mir-20a, Mir-20b, Rorc,
Stat3, Cd4+, Smad6, Smad7, Mtor, Foxo1, Foxp3, Gata3, Pparg, Inf&#x003b3;,
Hif1&#x003b1;, Il-17, Il-23, Il-1r, Il-21r, Il-21, Il-22, Il-6, T-Bet, Smad4,
Smad2, Stat5a, Stat5b, Stat1, Stat4, Stat6, In Cell Differentiation
Na&#x000ef;ve Cd4+ From Th17 Cells In Patients With Multiple Sclerosis In The
City Of Tabriz In Iran.</article-title>
<source><italic>World J Pharm Pharm Sci.</italic></source>
<year>2016</year>;<volume>5</volume>(<issue>2</issue>). <ext-link ext-link-type="uri" xlink:href="https://www.google.com/url?sa=t&#x00026;rct=j&#x00026;q=&#x00026;esrc=s&#x00026;source=web&#x00026;cd=2&#x00026;cad=rja&#x00026;uact=8&#x00026;ved=2ahUKEwjywv38utPfAhULtI8KHcPUCWUQFjABegQIABAC&#x00026;url=https%3A%2F%2Fwww.wjpps.com%2Fdownload%2Farticle%2F1454484092.pdf&#x00026;usg=AOvVaw1BTrnIjzw-kv0RIs3495fX">Reference Source</ext-link>
</mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shete</surname><given-names>A</given-names></name><name><surname>Thakar</surname><given-names>M</given-names></name><name><surname>Abraham</surname><given-names>PR</given-names></name><etal/></person-group>: <article-title>A review on peripheral blood CD4+ T lymphocyte
counts in healthy adult Indians.</article-title>
<source><italic>Indian J Med Res.</italic></source>
<year>2010</year>;<volume>132</volume>(<issue>6</issue>):<fpage>667</fpage>&#x02013;<lpage>75</lpage>.
<!--<pub-id pub-id-type="pmcid">3102453</pub-id>-->
<pub-id pub-id-type="pmid">21245613</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carter</surname><given-names>M</given-names></name><name><surname>Hughson</surname><given-names>G</given-names></name></person-group>: <article-title>CD4 Cell
Counts</article-title>.<year>2012</year>; NAM Publications.</mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Irwin</surname><given-names>M</given-names></name></person-group>: <article-title>Low CD4 counts: a variety of causes and their
implications to a multi-factorial model of AIDS.</article-title>
<source><italic>Br Med J online.</italic></source>
<year>2001</year>
<ext-link ext-link-type="uri" xlink:href="https://pdfs.semanticscholar.org/0f5f/6e94e9a77ff22ffe3ae192b6379b019f94ce.pdf?_ga=2.148468727.1319188841.1546583073-918838908.1546422978">Reference Source</ext-link>
</mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mair</surname><given-names>C</given-names></name><name><surname>Hawes</surname><given-names>SE</given-names></name><name><surname>Agne</surname><given-names>HD</given-names></name><etal/></person-group>: <article-title>Factors associated with CD4 lymphocyte counts in
HIV-negative Senegalese individuals.</article-title>
<source><italic>Clin Exp Immunol.</italic></source>
<year>2008</year>;<volume>151</volume>(<issue>3</issue>):<fpage>432</fpage>&#x02013;<lpage>440</lpage>.
<pub-id pub-id-type="doi">10.1111/j.1365-2249.2007.03573.x</pub-id>
<!--<pub-id pub-id-type="pmcid">2276971</pub-id>-->
<pub-id pub-id-type="pmid">18190600</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Naved</surname><given-names>SA</given-names></name><name><surname>Siddiqui</surname><given-names>S</given-names></name><name><surname>Khan</surname><given-names>FH</given-names></name></person-group>: <article-title>APACHE-II score correlation with mortality and
length of stay in an intensive care unit.</article-title>
<source><italic>J Coll Physicians Surg Pak.</italic></source>
<year>2011</year>;<volume>21</volume>(<issue>1</issue>):<fpage>4</fpage>&#x02013;<lpage>8</lpage>.
<pub-id pub-id-type="pmid">21276376</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kwizera</surname><given-names>A</given-names></name><name><surname>Nakibuuko</surname><given-names>J</given-names></name><name><surname>Ssemogerere</surname><given-names>L</given-names></name><etal/></person-group>: <article-title>Clinical characteristics and short-term outcomes
of hiv patients admitted to an african intensive care unit.</article-title>
<source><italic>Intensive Care Med Exp.</italic></source>
<year>2015</year>;<volume>3</volume>(<issue>S1</issue>):<fpage>A351</fpage>
<pub-id pub-id-type="doi">10.1186/2197-425X-3-S1-A351</pub-id>
<!--<pub-id pub-id-type="pmcid">4796737</pub-id>-->
</mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Feeney</surname><given-names>C</given-names></name><name><surname>Bryzman</surname><given-names>S</given-names></name><name><surname>Kong</surname><given-names>L</given-names></name><etal/></person-group>: <article-title>T-lymphocyte subsets in acute
illness.</article-title>
<source><italic>Crit Care Med.</italic></source>
<year>1995</year>;<volume>23</volume>(<issue>10</issue>):<fpage>1680</fpage>&#x02013;<lpage>1685</lpage>.
<pub-id pub-id-type="pmid">7587233</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hulley</surname><given-names>SB</given-names></name><name><surname>Cummings</surname><given-names>SR</given-names></name></person-group>: <article-title>Designing clinical
research.</article-title>Baltimore, Md: Williams &#x00026;
Wilkins;<year>1988</year>;<fpage>218</fpage>.</mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Manasa</surname><given-names>J</given-names></name><name><surname>Musabaike</surname><given-names>H</given-names></name><name><surname>Masimirembwa</surname><given-names>C</given-names></name><etal/></person-group>: <article-title>Evaluation of the Partec flow cytometer against
the BD FACSCalibur system for monitoring immune responses of human
immunodeficiency virus-infected patients in Zimbabwe.</article-title>
<source><italic>Clin Vaccine Immunol.</italic></source>
<year>2007</year>;<volume>14</volume>(<issue>3</issue>):<fpage>293</fpage>&#x02013;<lpage>298</lpage>.
<pub-id pub-id-type="doi">10.1128/CVI.00416-06</pub-id>
<!--<pub-id pub-id-type="pmcid">1828850</pub-id>-->
<pub-id pub-id-type="pmid">17267593</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mwanje</surname><given-names>KA</given-names></name><name><surname>Arthur</surname><given-names>K</given-names></name><name><surname>Irene</surname><given-names>AB</given-names></name><etal/></person-group>: <article-title>Association between CD4 T cell counts and the
immune status among adult critically ill HIV-negative patients in intensive
care units in Uganda</article-title>.<year>2018</year>
<pub-id pub-id-type="doi">10.17605/OSF.IO/JBMKP</pub-id>
</mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nishijima</surname><given-names>MK</given-names></name><name><surname>Takezawa</surname><given-names>J</given-names></name><name><surname>Hosotsubo</surname><given-names>KK</given-names></name><etal/></person-group>: <article-title>Serial changes in cellular immunity of septic
patients with multiple organ-system failure.</article-title>
<source><italic>Crit Care Med.</italic></source>
<year>1986</year>;<volume>14</volume>(<issue>2</issue>):<fpage>87</fpage>&#x02013;<lpage>91</lpage>.
<pub-id pub-id-type="doi">10.1097/00003246-198602000-00002</pub-id>
<pub-id pub-id-type="pmid">3943329</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Francois</surname><given-names>B</given-names></name><name><surname>Jeannet</surname><given-names>R</given-names></name><name><surname>Daix</surname><given-names>T</given-names></name><etal/></person-group>: <article-title>Interleukin-7 restores lymphocytes in septic
shock: the IRIS-7 randomized clinical trial.</article-title>
<source><italic>JCI Insight.</italic></source>
<year>2018</year>;<volume>3</volume>(<issue>5</issue>): pii: 98960.
<pub-id pub-id-type="doi">10.1172/jci.insight.98960</pub-id>
<!--<pub-id pub-id-type="pmcid">5922293</pub-id>-->
<pub-id pub-id-type="pmid">29515037</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lipsett</surname><given-names>PA</given-names></name><name><surname>Swoboda</surname><given-names>SM</given-names></name><name><surname>Dickerson</surname><given-names>J</given-names></name><etal/></person-group>: <article-title>Survival and functional outcome after prolonged
intensive care unit stay.</article-title>
<source><italic>Ann Surg.</italic></source>
<year>2000</year>;<volume>231</volume>(<issue>2</issue>):<fpage>262</fpage>&#x02013;<lpage>268</lpage>.
<pub-id pub-id-type="doi">10.1097/00000658-200002000-00016</pub-id>
<!--<pub-id pub-id-type="pmcid">1420995</pub-id>-->
<pub-id pub-id-type="pmid">10674619</pub-id></mixed-citation></ref></ref-list></back><floats-group><table-wrap orientation="portrait" id="T1" position="float"><label>Table 1. </label><caption><title>Baseline demographic and clinical characteristics among critically ill HIV
negative patients in Ugandan ICUs.</title></caption><table frame="hsides" rules="groups" content-type="article-table"><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">Patients, N (%) <xref rid="P24" ref-type="other">*</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Hospital </td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;IHK</td><td align="left" rowspan="1" colspan="1">32 (24.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;MNRH</td><td align="left" rowspan="1" colspan="1">70 (53.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;NHL</td><td align="left" rowspan="1" colspan="1">25 (19.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;UHI</td><td align="left" rowspan="1" colspan="1">3 (2.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender </td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Male </td><td align="left" rowspan="1" colspan="1">79 (60.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Female </td><td align="left" rowspan="1" colspan="1">50 (38.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Age in years <xref rid="P24" ref-type="other">&#x02020;</xref>
</td><td align="left" rowspan="1" colspan="1">45&#x000b1;18</td></tr><tr><td align="left" rowspan="1" colspan="1">Ethnicity </td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Black </td><td align="left" rowspan="1" colspan="1">122 (93.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Asian </td><td align="left" rowspan="1" colspan="1">3 (2.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Caucasian </td><td align="left" rowspan="1" colspan="1">2 (1.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Not
disclosed </td><td align="left" rowspan="1" colspan="1">3 (2.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Family income </td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Above $1 a
day</td><td align="left" rowspan="1" colspan="1">65 (50)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Below $1 a
day </td><td align="left" rowspan="1" colspan="1">59 (45.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Not
disclosed </td><td align="left" rowspan="1" colspan="1">6 (4.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Employment status </td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Professional
Job </td><td align="left" rowspan="1" colspan="1">35 (26.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Self
employed </td><td align="left" rowspan="1" colspan="1">60 (46.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Unemployed </td><td align="left" rowspan="1" colspan="1">31 (23.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Others</td><td align="left" rowspan="1" colspan="1">4 (3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Education status </td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;
University/tertiary </td><td align="left" rowspan="1" colspan="1">54 (41.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; Secondary </td><td align="left" rowspan="1" colspan="1">33 (25.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; Primary </td><td align="left" rowspan="1" colspan="1">34 (26.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; None </td><td align="left" rowspan="1" colspan="1">5 (3.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; Not
disclosed </td><td align="left" rowspan="1" colspan="1">4 (3.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking status </td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; Smoker </td><td align="left" rowspan="1" colspan="1">9 (6.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; Non-smoker </td><td align="left" rowspan="1" colspan="1">115 (88.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; Not
disclosed </td><td align="left" rowspan="1" colspan="1">6 (4.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">CD4 cell count time </td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;At 0800
h</td><td align="left" rowspan="1" colspan="1">90 (69.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;At 1000
h</td><td align="left" rowspan="1" colspan="1">37 (28.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Others </td><td align="left" rowspan="1" colspan="1">3 (2.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Time to death (days) <xref rid="P24" ref-type="other">&#x02020;</xref>
</td><td align="left" rowspan="1" colspan="1">6.6&#x000b1;6.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Status at 28 days </td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Alive </td><td align="left" rowspan="1" colspan="1">93 (71.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Dead </td><td align="left" rowspan="1" colspan="1">37 (28.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Admission source </td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Operating
theatre </td><td align="left" rowspan="1" colspan="1">48 (36.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Medical
wards </td><td align="left" rowspan="1" colspan="1">16 (12.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Obstetrics </td><td align="left" rowspan="1" colspan="1">2 (1.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Surgical
wards </td><td align="left" rowspan="1" colspan="1">12 (9.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Private
wing </td><td align="left" rowspan="1" colspan="1">3 (2.3)</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p id="P24">*Unless indicated. &#x02020;Data given as mean &#x000b1; standard
deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap orientation="portrait" id="T2" position="float"><label>Table 2. </label><caption><title>Showing indications for admission to ICU among critically ill HIV negative
patients in Ugandan ICUs.</title></caption><table frame="hsides" rules="groups" content-type="article-table"><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">Patients, n (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Post-operative care </td><td align="left" rowspan="1" colspan="1">60 (46.2)</td></tr><tr><td align="left" rowspan="1" colspan="1"> Central nervous system</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Stroke </td><td align="left" rowspan="1" colspan="1">10 (7.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Seizures </td><td align="left" rowspan="1" colspan="1">12 (9.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Head injury </td><td align="left" rowspan="1" colspan="1">29 (22.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Altered
mental status (unknown cause)</td><td align="left" rowspan="1" colspan="1">14 (10.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Cervical
spine injury </td><td align="left" rowspan="1" colspan="1">2 (1.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Other
neurological indication <xref rid="P25" ref-type="other">1</xref>
</td><td align="left" rowspan="1" colspan="1">9 (6.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardiovascular </td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Heart
failure with cardiogenic shock </td><td align="left" rowspan="1" colspan="1">4 (3.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Post
cardiac arrest </td><td align="left" rowspan="1" colspan="1">8 (6.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Acute
MI</td><td align="left" rowspan="1" colspan="1">1 (0.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Others
<xref rid="P25" ref-type="other">2</xref>
</td><td align="left" rowspan="1" colspan="1">5 (3.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Respiratory </td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;General
respiratory distress</td><td align="left" rowspan="1" colspan="1">35 (26.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Severe
pneumonia </td><td align="left" rowspan="1" colspan="1">8 (6.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Others
<xref rid="P25" ref-type="other">3</xref>
</td><td align="left" rowspan="1" colspan="1">14 (10.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Gastrointestinal </td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; Gastro
intestinal bleeding </td><td align="left" rowspan="1" colspan="1">6 (4.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;
Peritonitis </td><td align="left" rowspan="1" colspan="1">7 (5.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; Other
<xref rid="P25" ref-type="other">4</xref>
</td><td align="left" rowspan="1" colspan="1">5 (3.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Renal </td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; Acute
renal failure </td><td align="left" rowspan="1" colspan="1">15 (11.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Infections </td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; CNS
infections </td><td align="left" rowspan="1" colspan="1">3 (2.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; Cardiac </td><td align="left" rowspan="1" colspan="1">2 (1.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;
Respiratory infections </td><td align="left" rowspan="1" colspan="1">19 (14.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; Urinary
tract infections </td><td align="left" rowspan="1" colspan="1">1 (0.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;
Gastrointestinal infections </td><td align="left" rowspan="1" colspan="1">7 (5.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; Soft
tissue infections </td><td align="left" rowspan="1" colspan="1">2 (1.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; Blood
stream</td><td align="left" rowspan="1" colspan="1">8 (6.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0; Sepsis </td><td align="left" rowspan="1" colspan="1">26 (20)</td></tr><tr><td align="left" rowspan="1" colspan="1">Malnutrition </td><td align="left" rowspan="1" colspan="1">6 (4.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Tumors <xref rid="P25" ref-type="other">5</xref>
</td><td align="left" rowspan="1" colspan="1">7 (5.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Trauma surgery </td><td align="left" rowspan="1" colspan="1">19 (14.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Scheduled surgery </td><td align="left" rowspan="1" colspan="1">18 (13.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Emergency surgery </td><td align="left" rowspan="1" colspan="1">16 (12.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Post-partum hemorrhage </td><td align="left" rowspan="1" colspan="1">3 (2.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Other indications </td><td align="left" rowspan="1" colspan="1">6 (4.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Comorbidities </td><td align="left" rowspan="1" colspan="1">12(9.2)</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p id="P25"><sup>1</sup>Neurological diseases include brain tumors, cerebellar
lesion.<sup>2</sup>Cardiac diseases include arrhythmias, pericardial
effusion and myoma.<sup>3</sup>Respiratory diseases include aspiration
pneumonia, bilateral pneumothorax, pulmonary embolism, pulmonary edema and
other forms of chest trauma.<sup>4</sup>Gastrointestinal diseases include
intestinal obstruction, liver disease, cholelithiasis, and hepatitis, Other
indications include hemorrhage, burst abdomen, drug toxicity, electrolyte
imbalance, sick sinus syndrome.<sup>5</sup>Include brain and lung
tumors.</p></fn></table-wrap-foot></table-wrap><table-wrap orientation="portrait" id="T3" position="float"><label>Table 3. </label><caption><title>CD4 T cell counts among critically ill HIV-negative patients in Ugandan
ICUs.</title></caption><table frame="hsides" rules="groups" content-type="article-table"><thead><tr><th align="left" rowspan="1" colspan="1">CD4 count, cells/mm <sup>3</sup>
</th><th align="left" rowspan="1" colspan="1">Patients, n (%)</th><th align="left" rowspan="1" colspan="1">95 % CI</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Less than 100</td><td align="left" rowspan="1" colspan="1">4 (3.1)</td><td align="left" rowspan="1" colspan="1">0-6</td></tr><tr><td align="left" rowspan="1" colspan="1">100-499</td><td align="left" rowspan="1" colspan="1">67 (51.5)</td><td align="left" rowspan="1" colspan="1">42.8-60.3</td></tr><tr><td align="left" rowspan="1" colspan="1">500 and above </td><td align="left" rowspan="1" colspan="1">59 (45.4)</td><td align="left" rowspan="1" colspan="1">36.9-54.1</td></tr></tbody></table></table-wrap><table-wrap orientation="portrait" id="T4" position="float"><label>Table 4. </label><caption><title>Normal and low CD4 T cell counts among critically ill HIV negative patients
in Ugandan ICUs.</title></caption><table frame="hsides" rules="groups" content-type="article-table"><thead><tr><th align="left" rowspan="2" valign="top" colspan="1">Variable</th><th align="center" colspan="2" rowspan="1">CD4 count (cells/mm
<sup>3</sup>)</th><th align="left" rowspan="2" valign="top" colspan="1">P value <xref rid="P27" ref-type="other">*</xref>
</th></tr><tr><th align="left" rowspan="1" colspan="1">Normal &#x02265; 500
<break/>(N=59)</th><th align="left" rowspan="1" colspan="1">Low &#x0003c; 500 <break/>(N=71)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, years <xref rid="P27" ref-type="other">&#x02020;</xref>
</td><td align="left" rowspan="1" colspan="1">45.2&#x000b1;19.7</td><td align="left" rowspan="1" colspan="1">45.2&#x000b1;17.3</td><td align="left" rowspan="1" colspan="1">0.99</td></tr><tr><td align="left" rowspan="1" colspan="1">Outcome <xref rid="P27" ref-type="other">&#x02021;</xref>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Alive </td><td align="left" rowspan="1" colspan="1">41 (69.5)</td><td align="left" rowspan="1" colspan="1">52 (73.2)</td><td align="left" rowspan="1" colspan="1">0.64</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Dead </td><td align="left" rowspan="1" colspan="1">18 (30.5)</td><td align="left" rowspan="1" colspan="1">19 (26.8)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Time to death, days <xref rid="P27" ref-type="other">&#x02020;</xref>
</td><td align="left" rowspan="1" colspan="1">6.4&#x000b1;6.6</td><td align="left" rowspan="1" colspan="1">6.7&#x000b1;6.6</td><td align="left" rowspan="1" colspan="1">0.91</td></tr><tr><td align="left" rowspan="1" colspan="1">ICU stay (survivors) <xref rid="P27" ref-type="other">&#x02020;</xref>
</td><td align="left" rowspan="1" colspan="1">10.8&#x000b1;9.6</td><td align="left" rowspan="1" colspan="1">7.6&#x000b1;7.7</td><td align="left" rowspan="1" colspan="1">0.077</td></tr></tbody></table><table-wrap-foot><fn id="TFN5"><p id="P27">*For outcome, chi-squared test was used; for age, ICU stay and time
to death, Student&#x02019;s t-test was used. &#x02020;Data given as
mean&#x000b1;SD. &#x02021;Data given as n (%).</p></fn></table-wrap-foot></table-wrap><table-wrap orientation="portrait" id="T5" position="float"><label>Table 5. </label><caption><title>Multivariate analysis for relationship between CD4 and 28-day mortality among
critically ill HIV negative patients admitted to ICUs in Kampala.</title></caption><table frame="hsides" rules="groups" content-type="article-table"><thead><tr><th align="left" rowspan="1" colspan="1">Variable </th><th align="left" rowspan="1" colspan="1">28-day mortality, n/N (%)</th><th align="left" rowspan="1" colspan="1">aOR (95%)</th><th align="left" rowspan="1" colspan="1">P value </th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.2 (0-1.4)</td><td align="left" rowspan="1" colspan="1">0.093</td></tr><tr><td align="left" rowspan="1" colspan="1">CD4 count</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Normal (&#x02265;500 cells/mm
<sup>3</sup>) </td><td align="left" rowspan="1" colspan="1">18/59 (30.5)</td><td align="left" rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Low
(&#x0003c;500 cells/mm <sup>3</sup>)</td><td align="left" rowspan="1" colspan="1">19/71 (26.8)</td><td align="left" rowspan="1" colspan="1">1 (0.4-2.4)</td><td align="left" rowspan="1" colspan="1">0.990</td></tr><tr><td align="left" rowspan="1" colspan="1"> Head injury</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;No</td><td align="left" rowspan="1" colspan="1">25/101 (24.8)</td><td align="left" rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left" rowspan="1" colspan="1">12/29 (41.4)</td><td align="left" rowspan="1" colspan="1">3.1 (1.1-8.8)</td><td align="left" rowspan="1" colspan="1">0.033</td></tr><tr><td align="left" rowspan="1" colspan="1">Sepsis</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;
No</td><td align="left" rowspan="1" colspan="1">27/104 (26)</td><td align="left" rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left" rowspan="1" colspan="1">10/26 (38.5)</td><td align="left" rowspan="1" colspan="1">1.7 (0.6-5)</td><td align="left" rowspan="1" colspan="1">0.338</td></tr><tr><td align="left" rowspan="1" colspan="1">Gastrointestinal bleeding</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;No</td><td align="left" rowspan="1" colspan="1">3/6 (50)</td><td align="left" rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left" rowspan="1" colspan="1">3/6 (50)</td><td align="left" rowspan="1" colspan="1">3.7 (0.8-23.3)</td><td align="left" rowspan="1" colspan="1">0.167</td></tr><tr><td align="left" rowspan="1" colspan="1">Elective surgery</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;No</td><td align="left" rowspan="1" colspan="1">36/112 (32.1)</td><td align="left" rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Yes</td><td align="left" rowspan="1" colspan="1">1/18 (5.6)</td><td align="left" rowspan="1" colspan="1">0.2 (0-1.4)</td><td align="left" rowspan="1" colspan="1">0.093</td></tr><tr><td align="left" rowspan="1" colspan="1">Admission source</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Operating theatre</td><td align="left" rowspan="1" colspan="1">10/48 (20.8)</td><td align="left" rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Medical wards</td><td align="left" rowspan="1" colspan="1">5/16 (31.3)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Obstetrics</td><td align="left" rowspan="1" colspan="1">1/2 (50)</td><td align="left" rowspan="1" colspan="1">4.5 (0.2-85.1)</td><td align="left" rowspan="1" colspan="1">0.311</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Surgical wards</td><td align="left" rowspan="1" colspan="1">4/12 (33.3)</td><td align="left" rowspan="1" colspan="1">1.2 (0.2-6.2)</td><td align="left" rowspan="1" colspan="1">0.830</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;A&#x00026;E</td><td align="left" rowspan="1" colspan="1">12/42 (28.6)</td><td align="left" rowspan="1" colspan="1">0.8 (0.3-2.4)</td><td align="left" rowspan="1" colspan="1">0.716</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;Another hospital</td><td align="left" rowspan="1" colspan="1">5/16 (31.3)</td><td align="left" rowspan="1" colspan="1">8.5 (1.2-55.3)</td><td align="left" rowspan="1" colspan="1">0.026</td></tr></tbody></table><table-wrap-foot><fn id="TFN6"><p id="P29">aOR, adjusted odds ratio. In the model above, we adjusted for
hospital, reasons for ICU admission, admission source and smoking
history.</p></fn></table-wrap-foot></table-wrap><fig fig-type="figure" orientation="portrait" id="F1" position="float"><label>Figure 1. </label><caption><title>Receiver operator characteristic curve showing the feasibility of using CD4
cell counts to predict 24-hour mortality as compared to APACHE II score among
critically ill HIV-negative patients.</title></caption><graphic xlink:href="aasopenres-2-13997-g0000"/></fig></floats-group><sub-article id="REPORT26948" article-type="peer-review"><front-stub><article-id pub-id-type="doi">10.21956/aasopenres.13997.r26948</article-id><title-group><article-title>Reviewer response for version 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wade</surname><given-names>Djibril</given-names></name><xref ref-type="aff" rid="A8">1</xref><role>Referee</role><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1321-365X</contrib-id></contrib><aff id="A8">
<label>1</label>IRESSEF (Institute of Research in Health, Epidemiological
Surveillance and Training), Dakar, Senegal</aff></contrib-group><author-notes><fn fn-type="COI-statement" id="FN7"><p id="P39">
<bold>Competing interests: </bold>No competing interests were disclosed.</p></fn></author-notes><pub-date pub-type="epub"><day>5</day><month>7</month><year>2019</year></pub-date><permissions><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access peer review report distributed under the terms
of the Creative Commons Attribution Licence, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><custom-meta-group><custom-meta><meta-name>recommendation</meta-name><meta-value>approve-with-reservations</meta-value></custom-meta></custom-meta-group></front-stub><body><p id="P40">The article is well written and easily understandable. It deals with the use
of CD4 T-cell counts as a surrogate marker for 28 days mortality in HIV negative
patients which is really interesting and will bring a new usage of the CD4 T-cell
count which was mainly used to monitor immune system monitoring in HIV-infected
patients.</p><p id="P42"> I would just recommend adding reference to the studies&#x000a0;that
established the normal values of CD4 T-cell counts in the Ugandan population
(Nanzigu <italic>et al.</italic>, 2011<xref rid="R16" ref-type="bibr">1</xref>)
where the 95% reference ranges for absolute CD4 count was 418 - 2105 cells/&#x000b5;L.
In some countries mainly in resource-limited settings, people are exposed to a
variety of infectious diseases and other conditions including stress that may affect
CD4 count, and this is highly expected in patients attending ICUs. Given the normal
values of CD4 counts in Uganda, my final recommendation will be to please adjust
what you considered low CD4 counts.</p><p id="P43">I confirm that I have read this submission and believe that I have an
appropriate level of expertise to confirm that it is of an acceptable scientific
standard, however I have significant reservations, as outlined above.</p></body><back><ref-list><title>References</title><ref id="R16"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nanzigu</surname><given-names>S</given-names></name><name><surname>Waako</surname><given-names>P</given-names></name><name><surname>Petzold</surname><given-names>M</given-names></name><name><surname>Kiwanuka</surname><given-names>G</given-names></name><name><surname>Dungu</surname><given-names>H</given-names></name><name><surname>Makumbi</surname><given-names>F</given-names></name><name><surname>Gustafsson</surname><given-names>LL</given-names></name><name><surname>Eriksen</surname><given-names>J</given-names></name></person-group>: <article-title>CD4-T-Lymphocyte
Reference Ranges in Uganda and Its Influencing Factors</article-title>. <source><italic>Laboratory Medicine</italic></source>.<year>2011</year>;<volume>42</volume>(<issue>2</issue>) :
<fpage>94</fpage>-<lpage>101</lpage>
<pub-id pub-id-type="doi">10.1309/LMFT0VCE1UGO9YGD</pub-id>
</mixed-citation></ref></ref-list></back></sub-article><sub-article id="REPORT26831" article-type="peer-review"><front-stub><article-id pub-id-type="doi">10.21956/aasopenres.13997.r26831</article-id><title-group><article-title>Reviewer response for version 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Barugahare</surname><given-names>Banson</given-names></name><xref ref-type="aff" rid="A9">1</xref><role>Referee</role></contrib><aff id="A9">
<label>1</label>Faculty of Science and Education, Busitema University, Tororo,
Uganda</aff></contrib-group><author-notes><fn fn-type="COI-statement" id="FN8"><p id="P44">
<bold>Competing interests: </bold>No competing interests were disclosed.</p></fn></author-notes><pub-date pub-type="epub"><day>16</day><month>4</month><year>2019</year></pub-date><permissions><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access peer review report distributed under the terms
of the Creative Commons Attribution Licence, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><custom-meta-group><custom-meta><meta-name>recommendation</meta-name><meta-value>approve</meta-value></custom-meta></custom-meta-group></front-stub><body><p id="P45">I have reviewed the manuscript <italic>&#x0201c;Association between CD4 T
cell counts and the immune status among adult critically ill HIV-negative
patients in intensive care units in Uganda&#x0201d;. </italic>The finding that
CD4 T cell counts were generally low among HIV-negative critically ill patients but
did not predict ICU mortality is fundamental. This result calls for further
immunological studies. Nevertheless, I would like to recommend the authors to review
and make reference to the previous Ugandan population based CD4 normal value
studies. This information is available from a couple of studies by Tugume <italic>et
al.</italic> (1995<xref rid="R17" ref-type="bibr">1</xref>) and Lugada
<italic>et al.</italic> (2004<xref rid="R18" ref-type="bibr">2</xref>). The
background literature from these papers will inform the discussion and conclusion of
this study to a more acceptable position than it is now.</p><p id="P46">I confirm that I have read this submission and believe that I have an
appropriate level of expertise to confirm that it is of an acceptable scientific
standard.</p></body><back><ref-list><title>References</title><ref id="R17"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tugume</surname><given-names>SB</given-names></name><name><surname>Piwowar</surname><given-names>EM</given-names></name><name><surname>Lutalo</surname><given-names>T</given-names></name><name><surname>Mugyenyi</surname><given-names>PN</given-names></name><name><surname>Grant</surname><given-names>RM</given-names></name><name><surname>Mangeni</surname><given-names>FW</given-names></name><name><surname>Pattishall</surname><given-names>K</given-names></name><name><surname>Katongole-Mbidde</surname><given-names>E</given-names></name></person-group>: <article-title>Hematological
reference ranges among healthy Ugandans.</article-title>
<source><italic>Clin Diagn Lab Immunol</italic></source>.<year>1995</year>;<volume>2</volume>(<issue>2</issue>)
:<fpage>233</fpage>-<lpage>5</lpage>
<pub-id pub-id-type="pmid">7697535</pub-id></mixed-citation></ref><ref id="R18"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lugada</surname><given-names>ES</given-names></name><name><surname>Mermin</surname><given-names>J</given-names></name><name><surname>Kaharuza</surname><given-names>F</given-names></name><name><surname>Ulvestad</surname><given-names>E</given-names></name><name><surname>Were</surname><given-names>W</given-names></name><name><surname>Langeland</surname><given-names>N</given-names></name><name><surname>Asjo</surname><given-names>B</given-names></name><name><surname>Malamba</surname><given-names>S</given-names></name><name><surname>Downing</surname><given-names>R</given-names></name></person-group>: <article-title>Population-based
hematologic and immunologic reference values for a healthy Ugandan
population.</article-title>
<source><italic>Clin Diagn Lab Immunol</italic></source>.<year>2004</year>;<volume>11</volume>(<issue>1</issue>)
:<fpage>29</fpage>-<lpage>34</lpage>
<pub-id pub-id-type="pmid">14715541</pub-id></mixed-citation></ref></ref-list></back></sub-article><sub-article id="REPORT26753" article-type="peer-review"><front-stub><article-id pub-id-type="doi">10.21956/aasopenres.13997.r26753</article-id><title-group><article-title>Reviewer response for version 1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>D&#x000fc;nser</surname><given-names>Martin W.</given-names></name><xref ref-type="aff" rid="A10">1</xref><role>Referee</role></contrib><aff id="A10">
<label>1</label>Kepler University Hospital, Linz, Austria</aff></contrib-group><author-notes><fn fn-type="COI-statement" id="FN9"><p id="P47">
<bold>Competing interests: </bold>No competing interests were disclosed.</p></fn></author-notes><pub-date pub-type="epub"><day>26</day><month>2</month><year>2019</year></pub-date><permissions><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access peer review report distributed under the terms
of the Creative Commons Attribution Licence, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><custom-meta-group><custom-meta><meta-name>recommendation</meta-name><meta-value>approve-with-reservations</meta-value></custom-meta></custom-meta-group></front-stub><body><p id="P48">This is a very interesting work examining a novel aspect of intensive care
medicine. The authors need to be commended for their efforts. Despite several
positive aspects, I have some concerns and comments regarding the presented
manuscript. Comments are enumerated in the order they appear in the text:</p><p id="P49"> &#x000a0; <list list-type="order" id="L1"><list-item><p id="P50">I suggest that the authors include a separate
&#x0201c;Inclusion/Exclusion criteria&#x0201d; paragraph into the Methods
section. In this paragraph, they need to be clear about the criteria
used.&#x000a0;</p></list-item><list-item><p id="P51">One of, if not the most, important comments is that the authors
explain how they determined negative HIV-status. Was this always done by
negative HIV testing? Which test was used? Please give specific details
about this as it is key for your argumentation that you included only
HIV negative patients.&#x000a0;</p></list-item><list-item><p id="P52">Methods section, Study background paragraph: Please re-phrase
the sentence that participants gave written informed consent on behalf
of their critically ill patients. Did you mean that the next of kin gave
written informed consent on behalf of their critically ill
relatives?&#x000a0;</p></list-item><list-item><p id="P53">It is unclear how the authors performed a sample size
calculation for two groups if they designed a cohort study which
included only one arm. This is not possible. Please clarify or
omit.&#x000a0;</p></list-item><list-item><p id="P54">Please clearly describe your primary and secondary study
endpoint in the Methods section (e.g. the Statistical Analysis
paragraph).&#x000a0;</p></list-item><list-item><p id="P55">Table 1: In the text it is given that the CD4 count was
determined between 8 and 10 am. In Table 1 it is given that the CD4
count was measured at 8 or 10 am. Please clarify. After all, why is it
important whether CD4 count is determined at 8 or 10 am?&#x000a0;</p></list-item><list-item><p id="P56">Table 2: Please indicate n (%) for all summary diagnoses (e.g.
Central nervous system, cardiovascular, respiratory, etc.). Furthermore,
please specify 'general respiratory distress' (which is a very broad
term) and 'cardiac'.&#x000a0;</p></list-item><list-item><p id="P57">Results, page 5, first paragraph, last one before&#x000a0;sentence:
Please re-phrase as it is difficult to read.&#x000a0;</p></list-item><list-item><p id="P58">Results, page 5, subheading &#x0201c;Relationship between
[&#x02026;]&#x0201d;. The paragraph suggests that you tested an
association (multivariate analysis) and not a relationship.&#x000a0;</p></list-item><list-item><p id="P59">Table 3: What do you think about changing Table 3 into a
scatterblot figure?</p></list-item><list-item><p id="P60">Table 5: Did you include age as a binary variable? Why is the OR
below one for age? The higher the age the lower the mortality? This does
not make sense. The OR (CI95%) for medical wards is not given.&#x000a0;</p></list-item><list-item><p id="P61">Since CD4 count was only determined at a single time point after
ICU admission, it is unclear how the dynamics of this parameter is. Do
you have data to analyse the association between CD4 count and the
duration of hospital stay or disease duration before ICU
admission?&#x000a0;&#x000a0;</p></list-item><list-item><p id="P62">Figure 1 simply shows that both APACHE II and the CD4 count are
useless for prediction of 24-hour mortality. This could be mentioned in
the text but does not deserve presentation in a figure. Please omit.
Moreover, prediction of 24-hour mortality is not a common goal in
intensive care medicine. From the point of view of this reviewer, APACHE
II is not validated to predict mortality at this early stage of critical
illness.&#x000a0;</p></list-item><list-item><p id="P63">The limitation that this is a single centre study and that it is
unclear whether its results can be extrapolated to other centres and
regions should be mentioned.&#x000a0;</p></list-item><list-item><p id="P64">The conclusion paragraph of the text is too low and partly not
supported by the results of the study. Please rephrase the conclusion
paragraph of BOTH the abstract and the main text to: &#x0201c;In this
HIV-negative critically ill population, CD4 count was &#x0003c;500
cells/mm&#x000b3; in 51.5% of patients. We found no association between the
CD4 count and mortality at day 28.&#x0201d;&#x000a0;</p></list-item><list-item><p id="P65">Overall, the manuscript would benefit from proof reading by a
native English Speaker.</p></list-item></list>
</p><p id="P66">I confirm that I have read this submission and believe that I have an
appropriate level of expertise to confirm that it is of an acceptable scientific
standard, however I have significant reservations, as outlined above.</p></body></sub-article></article>